131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Active, not recruiting · NCT04743661 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, ependymoma, epithelial neoplasm, glioma, medulloblastoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-07-28 | NCT04743661 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| National Cancer Institute (NCI) | 3015 |
| Pediatric Brain Tumor Consortium | 2 |
| Y-mAbs Therapeutics | 12 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | United States | 226 |
| Cincinnati Children's Hospital Medical Center | Cincinnati | United States | 405 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |